Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda® (Pembrolizumab) in FAP-α Positive Solid Tumors
![Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda® (Pembrolizumab) in FAP-α Positive Solid Tumors](https://images.unsplash.com/photo-1535320903710-d993d3d77d29?auto=format&fit=crop&w=1600&q=70)
SEATTLE, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced a clinical trial collaboration agreement with Merck (NYSE: MRK), known as MSD outside of the United States and Canada.
Covered in this story
What has happened since
- Merck & Co. is up 1.6% since this was published, 38 days ago.
Price move measured from the close nearest publication to the latest quote.
Call it yourself
No calls on $CATX yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Perspective Therapeutics Inc →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.